Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Nasal Glucagon Promising for Hypoglycemia in Young Diabetics

By Marilynn Larkin (Reuters Health) | on March 24, 2016 | 0 Comment
Uncategorized
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Intranasal glucagon is emerging as a promising alternative to intramuscular glucagon as a rescue treatment for hypoglycemia in young people with type 1 diabetes, researchers report. For patients with type 1 diabetes and their families, fear of hypoglycemia may lead to less than optimal metabolic control, especially in young children, the researchers noted in a paper online in Diabetes Care.

You Might Also Like
  • ACEP Reviews Guidelines on Chest Wounds, Hypoglycemia, Positioning, Oxygen Use
  • Improvised Nasal Naloxone Devices Might Deliver Insufficient Medication
  • Point-of-Care Diagnostic Promising for Detection of Chikungunya Virus

“While severe hypoglycemic events are alarming in and of themselves, fear of hypoglycemia may be increased by the daunting task of treating such events with currently available glucagon emergency kits,” they write. Such kits require the user to reconstitute the powder in a diluent immediately before delivering an intramuscular injection.

To assess the safety and appropriate dosing of intranasal glucagon, the multicenter T1D Exchange Intranasal Glucagon Investigators recruited 48 youngsters with type 1 diabetes and divided them into three age cohorts: 4 to <8, 8 to <12, and 12 to <17. Participants in the two youngest cohorts were randomly assigned to receive either 2 or 3 mg intranasal glucagon in two separate sessions or a single weight-based dose of IM glucagon. Older children were randomly assigned to receive a 1 mg dose of IM glucagon in one session and a 3 mg dose of intranasal glucagon in the other session.

Before each session, participants received insulin to lower their blood glucose levels to less than 80 mg/dL. Five minutes after stopping the insulin, they were given either intranasal or IM glucagon.

The primary outcome of at least a 25 mg/dL rise in plasma glucose within 20 minutes was achieved in all 24 IM dosing sessions and in 58 of the 59 intranasal dosing sessions (a six-year-old blew his nose immediately after administration of the 2-mg intranasal dose, which resulted in a peak glucagon level 10-fold less than the mean detected in the other participants in his session).

Plasma glucagon levels increased rapidly within five minutes of both intranasal and IM treatments. Transient nausea occurred in 67 percent of the IM sessions versus 42 percent of the intranasal sessions, and both efficacy and safety of the 2-mg and 3-mg intranasal doses were similar in the youngest participants. The authors concluded that “a single 3-mg intranasal dose appears to be appropriate for use across the entire 4 to <17 year range.”

The intranasal system is currently in Phase III trials, according to Deirdre Ibsen, senior director of product development for Lilly, which acquired worldwide rights to the system from Locemia Solutions in October 2015.

Pages: 1 2 | Single Page

Topics: DiabetesGlucagonintramuscular glucagonIntranasal glucagonPediatricsType 1type 1 diabetes

Related

  • Case Report: When Syncope Gets Hairy

    June 17, 2025 - 0 Comment
  • Influenza, Muscle Pain, and an Elevated Serum Creatine Kinase

    May 10, 2025 - 0 Comment
  • When Do Pediatric Ventriculoperitoneal Shunts Fail?

    November 7, 2024 - 0 Comment

Current Issue

ACEP Now: June 2025 (Digital)

Read More

No Responses to “Nasal Glucagon Promising for Hypoglycemia in Young Diabetics”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Current Issue

ACEP Now: June 2025 (Digital)

Read More

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603